Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine

[PR Newswire] – BEIJING, Feb. 26, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 (EV71) vaccine have bee more

View todays social media effects on SVA

View the latest stocks trending across Twitter. Click to view dashboard

See who Sinovac is hiring next, click here to view